comparemela.com

Latest Breaking News On - Juventas cell therapy ltd - Page 4 : comparemela.com

Juventas Cell Therapy Announces the Approval of Its First Cell Therapy Product - Inaticabtagene Autoleucel by China NMPA

Juventas Cell Therapy Ltd. announces China National Medical Product Administration (NMPA) has approved its New Drug Application (NDA) for Inatic.

China
Shanghai
Beijing
Tianjin
Inaticabtagene-autoleucel
Inaticabtagene-autoleucelis
Wang-jianxiang
Lyv-lulu
Juventas-cell-therapy-ltd
China-national-medical-product-administration
Institute-of-hematology-blood-diseases-hospital
China-national-medical-products-administration

CASI PHARMACEUTICALS ANNOUNCES MARKET APPROVAL OF CNCT19 BY CHINA NMPA

BEIJING, Nov. 8, 2023 /PRNewswire/ CASI Pharmaceuticals Inc. (Nasdaq: CASI), a biopharmaceutical company focused on developing and commercializ.

China
Wuxi
Jiangsu
Beijing
United-states
Chinese
Inaticabtagene-autoleucel
Rui-zhang
Pharmaceuticals-china-co-ltd
Nasdaq
China-national-medical-products-administration
Pharmaceuticals-inc

CASI PHARMACEUTICALS ANNOUNCES MARKET APPROVAL OF CNCT19 BY CHINA NMPA

CASI Pharmaceuticals Inc. , a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, is thrilled to announce a major milestone in its partnership with Juventas Cell Therapy Ltd..

China
United-states
Wuxi
Jiangsu
Beijing
Chinese
Rui-zhang
Inaticabtagene-autoleucel
European-medicines-agency
Drug-administration
Exchange-commission
Juventas-cell-therapy-ltd

CASI PHARMACEUTICALS' PARTNER JUVENTAS ANNOUNCES NEW DRUG APPLICATION FOR CNCT19 ACCEPTED BY CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION

/PRNewswire/ CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics.

China
Beijing
United-states
American
Wang-jianxiang
Rui-zhang
Inaticabtagene-autoleucel
Institute-of-hematology
Nasdaq
Pharmaceuticals-china-co-ltd
China-national-medical-products-administration
Juventas-cell-therapy-ltd

CASI PHARMACEUTICALS ANNOUNCES FULL-YEAR 2021 FINANCIAL RESULTS AND FOURTH QUARTER 2021 EVOMELA® REVENUE

/PRNewswire/ CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics.

China
Beijing
United-states
Wuxi
Jiangsu
United-kingdom
Xuan-yang
Liaoning
France
Chinese
Rui-zhang
Drug-administration

vimarsana © 2020. All Rights Reserved.